Health ❯ Healthcare ❯ Cardiology

Hypertrophic Cardiomyopathy

Aficamten Myosin Inhibitors Myqorzo Patient Outcomes Imaging Techniques Obstructive Hypertrophic Cardiomyopathy Diagnosis Clinical Research Risk Prediction Biomarkers

Aficamten Improves Symptoms and Exercise Capacity in Nonobstructive HCM

Cytokinetics plans a U.S. supplemental filing following results that raise the need for strict ejection‑fraction monitoring.

UK Clears Aficamten (MYQORZO) for Symptomatic Obstructive Hypertrophic Cardiomyopathy

NHLBI-Backed JAMA Study Finds MRI and Blood Tests Improve HCM Risk Prediction

FDA Approves Cytokinetics’ Myqorzo for Obstructive Hypertrophic Cardiomyopathy

Aficamten Tops Metoprolol in Obstructive HCM as Mavacamten Misses in Nonobstructive Trial